经动脉化疗栓塞(TACE)联合射频消融(RFA)治疗小肝癌:与TACE或RFA单药治疗的比较
本研究比较TACE联合RFA(TACE-RFA)与TACE或RFA单药治疗小肝癌(≤3 cm、≤3个)的安全性和疗效。TACE-RFA组住院时间更长、需用药的不适更频繁、总体并发症更多,但主要并发症率和1个月Child-Pugh评分无显著差异;1个月、6个月和1年肿瘤反应与RFA相似且优于TACE。作者认为TACE-RFA可能适用于经选择的患者,尤其是不适合RFA单药治疗的小肝癌患者。
要点
- 联合TACE-RFA治疗小肝癌的1个月、6个月和1年肿瘤反应与RFA单药相似,优于TACE单药。
- TACE-RFA组住院时间更长、需用药的不适更频繁,总体并发症频率高于TACE(P=0.006)和RFA(P=0.009)。
- 三组主要并发症率和1个月Child-Pugh评分无显著差异(P分别为0.094和0.162)。
核心结论
- TACE-RFA似乎导致更频繁的需用药不适、更长的住院时间和更频繁的并发症,多于TACE或RFA单药治疗。
- TACE-RFA的肿瘤反应似乎与RFA相似,且优于TACE单药治疗。
- 因此,作者认为TACE-RFA治疗小肝癌可能适用于经选择的患者,尤其是不适合RFA单药治疗的小肝癌患者。
研究设计与样本
- 本研究纳入34例联合TACE和RFA(TACE-RFA)、87例TACE和136例超声引导RFA,用于治疗2009年3月至8月间的小肝癌(≤3 cm,≤3个)。
- 评估并比较每种治疗的安全性(Child-Pugh评分反映肝脏功能储备、需用药的患者不适、住院时间和并发症)和疗效(1个月、6个月和1年肿瘤反应)。
诊断标准与关键数值
- 1个月、6个月和1年肿瘤反应:TACE-RFA与RFA相似,优于TACE。
- 总体并发症频率:TACE-RFA高于TACE(P=0.006)和RFA(P=0.009)。
- 主要并发症率:三组间无统计学差异(P=0.094)。
- 1个月随访Child-Pugh评分:三组间无显著差异(P=0.162)。
临床应用与阅片要点
- 作者认为TACE-RFA治疗小肝癌可能适用于经选择的患者,尤其是不适合RFA单药治疗的小肝癌患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To compare the safety and efficacy of combined transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma (HCC) with those of TACE or RFA monotherapy.
METHODS: This study included 34 combined TACE and RFA (TACE-RFA), 87 TACE, and 136 ultrasound-guided RFA, which were performed to treat HCC (≤ 3 cm, 3 or fewer) between March and August 2009. The safety (Child-Pugh score indicating hepatic functional reserve, patient discomfort requiring medication, duration of hospitalization, and complications) and efficacy (1-month, 6-month, and 1-year tumor responses) profiles of each treatment were evaluated and compared.
RESULTS: TACE-RFA group showed longer hospital stay and more frequent patient discomfort requiring medication than TACE or RFA group (P < 0.001). The frequency of overall complications after TACE-RFA was higher than TACE (P = 0.006) or RFA (P = 0.009). There were no statistical differences in major complication rates between the three groups (P = 0.094). Child-Pugh score at 1-month follow-up showed no significant difference between the three groups (P = 0.162). 1-month, 6-month, and 1-year tumor responses of TACE-RFA were similar to those of RFA and better than those of TACE.
CONCLUSIONS: TACE-RFA appears to result in more frequent patient discomfort requiring medication, longer hospital stay, and more frequent complications than TACE or RFA monotherapy. Tumor response of TACE-RFA seems to be similar to that of RFA and better than TACE monotherapy. Thus, TACE-RFA for treating small HCC may be required for the selected patients, especially patients with small HCC ineligible for RFA monotherapy.
引用
- Kim W, Cho SK, Shin SW, et al. Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: comparison with TACE or RFA monotherapy. Abdom Radiol (NY). 2019. PMID: 30806742. doi:10.1007/s00261-019-01952-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。